Efficacy and safety of liraglutide versus placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment

ovo Nordisk A/S0 个研究点目标入组 274 人开始时间: 2012年4月20日最近更新: 2013年11月18日

适应症

试验速览

暂无简介。

•Subjects diagnosed with type 2 diabetes with stable diabetes treatment (unchanged medication and unchanged dose) for 90 days prior to the screening visit including:
•- Monotherapy or any duo-combinations of metformin and/or SUs and/or pioglitazone. Metformin should be used with caution in subjects with moderate renal failure and must be used in accordance with local metformin labelling or guidelines.
•- Monotherapy or any combinations of metformin and/or pioglitazone and/or basal or premix insulin. Insulin adjustments (total daily dose) =10% within 90 days prior to the screening visit as confirmed by the investigator are acceptable. Metformin should be used with caution in subjects with moderate renal failure and must be used in accordance with local metformin labelling or guidelines. Combination of pioglitazone and insulin should be used with caution and according to local labelling or guidelines.
•HbA1c 7–10% (both inclusive).
•Moderate renal impairment diagnosed more than 90 days prior to the screening visit and confirmed by an eGFR of 30-59 mL/min/1.73 m^2 per MDRD formula at the screening visit.
•BMI 20–45 kg/m^2 (both inclusive).
•Male or female, age 18-80 years (both inclusive).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 164
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 110

•Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator.
•Treatment with antidiabetic medication(s) other than stated in the inclusion criteria in a period of 90 days prior to screening. Previous short-term (= 7 days in total) treatment with rapid- or short-acting insulin in connection with intercurrent illness is allowed at the discretion of the investigator.
•Impaired liver function, defined as ALAT =2.5 times upper normal limit.
•History of chronic pancreatitis or idiopathic acute pancreatitis.
•Within the past 180 days any of the following: Episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack (TIA) or other significant cardiovascular event (including e.g. arrhythmias or conduction delays on ECG).
•Heart failure defined as New York Heart Association (NYHA) class IV.
•A systolic blood pressure =180 mmHg or a diastolic blood pressure =100 mmHg.
•Rapidly progressing renal disease (e.g., acute glomerulonephritis) at the discretion of the investigator.
•Use of immunosuppressive treatment within 90 days prior to screening.
•Diagnosis or treatment for cancer in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer).
•Proliferative retinopathy or maculopathy requiring acute treatment as judged by the investigator.

发起方